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Abstract
Exploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry
activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological
assays, and identification of new starting points for chemical exploration. Extracting chemical and biological entities from
patents through manual extraction by expert curators can take substantial amount of time and resources. Text mining
methods can help to ease this process. To validate the performance of such methods, a manually annotated patent corpus
is essential. In this study we have produced a large gold standard chemical patent corpus. We developed annotation
guidelines and selected 200 full patents from the World Intellectual Property Organization, United States Patent and
Trademark Office, and European Patent Office. The patents were pre-annotated automatically and made available to four
independent annotator groups each consisting of two to ten annotators. The annotators marked chemicals in different
subclasses, diseases, targets, and modes of action. Spelling mistakes and spurious line break due to optical character
recognition errors were also annotated. A subset of 47 patents was annotated by at least three annotator groups, from
which harmonized annotations and inter-annotator agreement scores were derived. One group annotated the full set. The
patent corpus includes 400,125 annotations for the full set and 36,537 annotations for the harmonized set. All patents and
annotated entities are publicly available at www.biosemantics.org.
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Introduction
A substantial number of patent applications are filed every year
by the pharmaceutical sector [1]. Exploring the chemical and
biological space covered by these patents is crucial in early-stage
medicinal chemistry activities [1,2]. Patent specifications are one
of many information sources needed to progress drug discovery
projects. Patent analysis can provide understanding of compound
prior art, novelty checking, validation of biological assays, and
identification of new starting points for chemical exploration [3].
Extracting chemical and biological entities from patents is a
complex task [4,5]. Different approaches are currently used
including manual extraction by expert curators, text mining
supported by chemical and biological named entity recognition,
or combinations thereof [6]. Chemical patents are complex legal
documents that can contain up to hundreds of pages. The European
Patent Office (EPO) [7], the pharmaceutically relevant patents
within the United States Patent and Trademark Office (USPTO)
[8], and the World Intellectual Property Organization (WIPO) [9]
can be accessed and queried on-line via their websites. The patents
are freely available from the patent offices, usually as XML, HTML
or image PDFs, although EPO limits the number of downloads per
week for non-paying users. Using optical character recognition
(OCR), the image PDFs can be prepared for text mining. In fact, the
available HTML and XML documents are mainly the OCR output
prepared and published by the patent offices.
However, the text mining itself is a rather challenging task
[10,11]. Methods and their output can suffer dramatically from
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the large number of complex chemical names, term ambiguities,
complex syntactic structures and OCR errors [12].
To validate the performance of named entity recognition
techniques, the availability of a manually annotated patent corpus
is essential [13]. Producing such annotated text is laborious and
expensive. Most of the prior focus on corpora development has
been on genes and proteins and less effort has been put into
creating corpora for chemical terms [14]. Among the latter efforts,
Kim et al. [15] in 2003 developed the GENIA corpus consisting of
several classes of chemicals. The BioIE corpus by Kulick et al. [16]
was made available in 2004 and included annotations of chemicals
and proteins. In 2008, Kola´rik et al. [17] released a small corpus of
scientific abstracts annotated with chemical compounds. Recently,
the CHEMDNER corpus, annotated with different classes of
chemicals, was made available as part of the BioCreative challenge
[18]. All these corpora consist of scientific abstracts from Medline.
In a collaborative project between the EPO and the Chemical
Entities of Biological Interest (ChEBI) in 2009 [19] a chemical
patent corpus containing annotations of chemical entities and, if
possible, their mapping to ChEBI chemical compounds [20] was
developed. In a later study [21], the updated version of ChEBI
[22] was used to increase the number of mappings. A larger patent
corpus was developed in 2012 by Kiss et al. [12] which included
name entity recognition of generic chemical compounds.
To our knowledge, the development of a gold standard patent
corpus has not been systematically tackled before. Among the
obvious reasons for this are the length and complexity of the
patent text. In previous attempts only limited number of chemicals
have been annotated and subclasses have not been defined. Other
biological entities such as diseases or modes of actions have not
been included and errors due to misspellings or OCR procedures
have not been considered. Most previous studies on annotated
Table 1. Target class distribution of the 8,066 patents from which the final set was drawn.
Target class Number of patents Final selection
GPCR 3,569 20
Protease 1,093 17
Kinase 1,046 12
Ion-Channel 433 14
Oxidoreductase 404 17
Hydrolase 364 15
NHR 349 15
Transporters 323 18
Other 218 11
Transferase 152 12
Phosphatase 65 17
Drugs from Sayle et al. [24] 50 32
Total 8,066 200
doi:10.1371/journal.pone.0107477.t001
Figure 1. Example patent text with pre-annotations as shown by the Brat annotation tool.
doi:10.1371/journal.pone.0107477.g001
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corpora did not provide insights into inter-annotator agreement.
This information would be valuable in assessing and comparing
the performance of text mining applications.
Here we present a gold standard annotated corpus of 200 full
patents for benchmarking text mining performance. The patent
corpus includes annotation of chemicals with subclasses, diseases,
targets and modes of action. Also spelling mistakes and spurious
line break due to OCR errors are annotated within this corpus.
The full-text patents and annotated entities are publicly available
at www.biosemantics.org.
Methods and Materials
Corpus development strategy
The development of the gold standard patent corpus consisted
of several phases. First, annotation guidelines were developed and
a set of 200 diverse patents was chosen. The patents were pre-
annotated automatically and made available to four independent
annotator groups. The annotator groups could choose to consider
or disregard the pre-annotations. Two patents were used to refine
the annotation guidelines. The remaining patents were distributed
between multiple annotator groups in a way that a subset of 47
patents was annotated by at least three groups, from which
harmonized annotations were derived. Inter-annotator agreement
scores between the annotator groups and against the harmonized
set were computed. One annotator group annotated the complete
set of patents.
Patent corpus selection
The GVK BIO target class database [23] was used as a starting
point for patent corpus selection. Patents from the EPO [7],
USPTO [8], and WIPO [9] are available through this database,
which includes relationships between documents, assays, chemical
structures, assignees and protein targets, manually abstracted by
expert curators [1]. Within the database, patents are binned based
on different classes of protein families such as kinases or GPCRs
[23].
All English language patents containing between 10 and 200
exemplified compounds, with a named primary target, were
selected from the GVK BIO database. We made sure that all
compounds had a molecular weight below 1000 to bias towards
small-molecule patents. We did not specify limits on the time of the
application. Overall 28,695 patents fulfilled the above criteria.
Chemical patents are known to include long sentences with
complex syntactic structure [12]. Individual companies may have
different ways of writing patents and we wanted to include
diversity over assignees in the corpora. Therefore, if assignees had
written multiple patents for one primary target, only one was
randomly kept and the rest was disregarded.
Based on these selection criteria we were left with 8,016 patents
grouped in 11 target classes. To make sure that a collection of well-
known patents are included in the corpus, 50 drug patents from
Sayle et al. [24] were added. Subsequently patents were randomly
picked from each target group with a minimum of 10 patents per
group. The diversity of the final selection is shown in Table 1. The
final set consists of 121 USPTO, 66 WIPO, and 13 EPO patents,
and contains over 11,500 pages and 4.2 million words.
The patents were downloaded from the sources (EPO, USPTO,
and WIPO) in XML format. Whenever multiple consecutive line
breaks were encountered, they were replaced with a single line
break. Images were also removed for all patents.
Annotated entities
We annotated all compounds, diseases, protein targets, and
modes of actions (MOA) mentioned in the patents. Compounds
were assigned to a number of subclasses based on how they are
generated: systematic identifiers and non-systematic identifiers
[25]. The following systematic identifiers were annotated: IUPAC
names [26], such as ‘‘ammonium phosphate’’ or ‘‘2-[2-(4-{2-
[ethyl(2-fluorobenzyl)amino]-2-oxoethoxy}phenyl)ethoxy]benzoic
acid’’; SMILES notations [27], such as ‘‘n1c[nH]cc1’’; and InChI
strings [28,29], such as ‘‘InChI = 1S/C2H6O/c1-2-3/h3H,2H2,
1H3’’. We also annotated the following non-systematic identifiers:
trademarks, such as ‘‘Aspirin’’, ‘‘Mesupron’’, and ‘‘Arimidex’’;
abbreviations, such as ‘‘DCM’’, ‘‘TBTU’’ and ‘‘DMAP’’; CAS
numbers [30,31], such as ‘‘7732-18-5’’; formulas, such as
‘‘MgSO4’’; registry numbers, such as ‘‘ly256548’’; and generic
names, such as ‘‘iodotamoxifen’’, ‘‘cycloalkylamines’’ and ‘‘race-
mate’’. Any mention of diseases, such as ‘‘diabetes’’, protein
targets, such as ‘‘trypsin’’, and MOAs, such as ‘‘antagonist’’, were
also annotated. OCR errors were also annotated in terms of
spelling mistakes and spurious line breaks.
Table 2. Number of annotated terms and unique terms within the harmonized set prior to disambiguation.
Entity type Annotated terms Unique terms
IUPAC 14,423 5,365
Generic 7,959 880
Disease 3,777 1,257
Target 3,227 705
Trademark 2,273 987
Abbreviation 1,460 153
Formula 1,069 171
MOA 1,014 211
Registry Number 108 90
SMILES 21 21
CAS 6 5
InChI 0 0
Total 35,337 9,845
doi:10.1371/journal.pone.0107477.t002
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Annotation guidelines
Initial annotation guidelines were developed based on previous
work [14,16–18]. Two patents (US5023269 [32] and US4659716
[33]) were randomly chosen from the patent corpus for training
the annotators and fine-tuning the annotation guidelines. The
following rules were defined:
1. When an entity is nested or has an overlap with another entity,
annotate the entity that is more specific and informative. For
example ‘‘5-HT1D’’ should not be annotated as target when it
is embedded within the target annotation of ‘‘5-HT1D
Serotonin Receptors’’.
2. Annotate simple IUPAC names such as ‘‘water, ‘‘ammonia’’,
and ‘‘ethanol’’.
3. Prefixes should be included within annotations, for example
‘‘1,4-’’ in ‘‘1,4-butanediol’’.
4. Simple formulas such as ‘‘NaOH’’ and ‘‘(NH4)2SO4’’, should
be annotated as Formulas.
5. Counterions, such as ‘‘acetate’’, ‘‘oxalate’’, ‘‘propionate’’,
should be annotated as IUPAC names.
6. Generic structures such as ‘‘4-halo-phenol’’ or ‘‘xylene’’, should
be annotated as Generic names.
7. Polymers, e.g., ‘‘Polystyrene’’, should be annotated as Generic
names.
8. Trivial names, e.g., ‘‘Sildenafil’’, should be annotated as
IUPAC names.
9. Enumerations, like ‘‘hydrochloric’’ and ‘‘hydrobromic’’ in
‘‘include inorganic acids such as hydrochloric, hydrobromic’’,
should be annotated as IUPAC names.
10. Elements like ‘‘N’’, ‘‘O’’, and ‘‘C’’ should not be annotated.
11. Misspelled terms should be annotated as spelling mistakes
(e.g., ‘‘hydrobroml:c’’).
12. Annotations spanning over multiple lines because of
spurious line breaks should be annotated as one term and
be tagged with spurious line breaks.
13. Extra white space should be annotated as spelling mistakes
(e.g., ‘‘hydro bromic’’).
14. Do not annotate a term if it is splitted due to reasons other
than OCR errors.
15. All symbols such as comma, charge symbol or brackets,
should be included in the annotation (e.g., ‘‘n1c[nH]cc1’’).
Annotation process
Each patent was automatically pre-annotated using LeadMine
(NextMove Software, UK) [34]. LeadMine can identify chemicals,
protein targets, genes, species, company names, and also has the
ability to recognise terms with spelling mistakes and suggest
Table 3. Inter-annotator agreement (F-score) without ambiguity resolution.
AstraZeneca Fraunhofer GVK BIO NextMove
Fraunhofer 0.42
GVK BIO 0.60 0.39
NextMove 0.50 0.69 0.52
Harmonized 0.78 0.64 0.74 0.72
doi:10.1371/journal.pone.0107477.t003
Table 4. The effect of the disambiguation process on the annotations.
Rules Type Affected Terms Affected Annotations
Add IUPAC 52 2,275
annotation Abbreviation 29 1,631
Generic 67 976
Trademark 71 442
Disease 4 387
MOA 2 203
Formula 25 177
Registry Number 28 111
Target 19 32
Remove Elements 23 2,499
annotation IUPAC 7 103
Trademark 3 101
Generic 2 67
Target 1 1
Total 333 9,005
doi:10.1371/journal.pone.0107477.t004
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corrections. This increases the likelihood of detecting terms with
OCR errors by the human annotator.
A pre-annotation consists of the span of text corresponding with
the entity and its location within the text file. The following entity
types were pre-annotated by LeadMine: IUPAC names, trivial
names, CAS numbers, registry numbers, generic names, formulas,
and targets. We did not pre-annotate SMILES and InChIs, as they
are rarely present in patents. Diseases, and MOAs were also not
included as this was not possible through our version of LeadMine.
For the annotation process the Brat rapid annotation tool
(version 1.3) was used [35]. Brat allows online annotation of text
using pre-defined entity types. It can display the pre-annotations
and annotators can add new annotations and modify or delete the
pre-annotated entities. To reduce mistakes and increase readabil-
ity each entity type was marked by a specific color. For
performance reasons we split the patents into pages with 50
paragraphs for display in Brat. Figure 1 shows a screenshot of Brat
with pre-annotations.
Patents were annotated by annotators from four groups:
AstraZeneca, Fraunhofer, GVK BIO, and NextMove. The
GVK BIO annotation group consisted of ten annotators, while
the other annotator groups had two annotators. One annotator
group (Fraunhofer) chose to disregard the pre-annotations made
by LeadMine. The patents were distributed between annotators
within a group, such that each patent was annotated by only one
annotator in a group. In the context of this paper, annotator group
will refer to any individual annotator within the group.
Annotators had to correct any misidentified pre-annotation and
had to add annotations that were missed in the pre-annotation
step. Entities containing misspellings or spurious line breaks were
separately annotated.
Resolving misannotation of ambiguous terms
After the completion of the annotations by all groups, a group of
annotators reviewed the results to reduce the number of
ambiguous terms within the corpus. A term is defined as
ambiguous if different groups annotated it with different entity
types throughout the corpus.
A list of ambiguously annotated terms was compiled and
annotators were asked to review the list only based on the different
entity types assigned to each ambiguous term (i.e., the context of
the terms was not provided). The annotators had to classify each
term in one of three groups:
1- None of the entity types assigned to the term is
applicable. All annotations of the term were removed
from the corpus. For example, ‘‘nitrogen’’ was annotat-
ed as both IUPAC and Generic multiple times
throughout the corpus. However, either entity type is
incorrect since the term is an element. Therefore
annotations of nitrogen are removed from the corpus.
2- One entity type is applicable. All occurrences of the
term within the corpus were assigned to this entity type.
For example, the term ‘‘DMF’’ was assigned 43 times as
Trademark, 289 times as Abbreviation, and once as
Formula. Regardless of the context of the text, DMF is
an abbreviation and therefore the entity type of the term
was changed to Abbreviation throughout the corpus.
3- More than one entity type is applicable. Only term
annotations with an entity type that is not applicable,
were removed throughout the corpus. For example, the
term ‘‘5-ht’’ has been annotated 17 times as Abbrevi-
ation, 25 times as Generic, and 23 times as Target.
Depending on the context of the text, the term can be
either Target or Abbreviation but not Generic. There-
Table 5. Inter-annotator agreement after ambiguity resolution.
AstraZeneca Fraunhofer GVK BIO NextMove Harmonized
AstraZeneca + 0.04 + 0.09 + 0.08 + 0.06
Fraunhofer 0.46 + 0.05 + 0.03 + 0.01
GVK BIO 0.69 0.44 + 0.06 + 0.05
NextMove 0.58 0.72 0.58 + 0.03
Harmonized 0.84 0.65 0.79 0.75
The lower left triangle presents the inter-annotator agreement scores (F-score). The upper right triangle shows the improvement gained through disambiguation.
doi:10.1371/journal.pone.0107477.t005
Table 6. Inter-annotator agreement (F-score) between the harmonized set and the annotator groups for the main entity types.
AstraZeneca Harmonized Fraunhofer Harmonized GVK BIO Harmonized NextMove Harmonized
Overall 0.84 0.65 0.79 0.75
Chemicals 0.89 0.65 0.78 0.75
Systematic 0.94 0.81 0.91 0.93
Non-systematic 0.85 0.38 0.68 0.56
Disease 0.47 0.82 0.87 0.86
Targets 0.76 0.57 0.81 0.86
MOA 0.65 0.29 0.67 0.17
doi:10.1371/journal.pone.0107477.t006
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fore all annotations of the term as Generic were
removed from the corpus.
Harmonization
To develop the gold standard corpus, the annotations of the 47
patents annotated by more than three groups were merged into a
harmonized set. The centroid algorithm described by Lewin et al.
[36] was used for this purpose.
Briefly, the algorithm tokenizes the annotations of different
annotators at the character level and counts the number of
agreeing annotators over pairs of adjacent annotation-internal
characters [36]. Calculating votes over annotation-internal char-
acter pairs and not individual characters, guarantees that
boundaries (starting and ending position of an annotated entity
type) are considered in situations where two terms are annotated
directly adjacent to each other [36]. The harmonized annotation
consists of the characters pairs that have a vote equal to or larger
than a specified threshold. In this work, we used a voting threshold
of two, i.e., at least two annotators had to agree on the annotation.
The centroid algorithm was executed separately for each entity
type. Therefore votes were only calculated if at least two
annotators annotated a term with the same entity type.
Inter-annotator agreement
Similar to Corbett et al. [14] and Kola´rik et al. [17], we used the
F-score (harmonic mean of recall and precision) to calculate the
inter-annotator agreement between the annotator groups and
between each annotator group and the harmonized set. For the
comparison of two sets of annotations, one set was arbitrarily
chosen as the gold standard (this choice does not affect the F-
score). An annotation in the other set was counted as true positive
if it was identical to the gold standard annotation, i.e., if both
annotations had the same entity type and the same start and end
location. If a gold standard annotation was not given, or not
rendered exactly in the other set (i.e., non-matching boundaries or
a different entity type), it was counted as false negative; if an
annotation found in the other set did not exactly match the gold
standard, it was counted as false positive.
Results
Patent distribution among groups
The number of annotated patents varied between annotation
groups. Apart from the two patents used for training, 27 patents
were annotated by NextMove, 36 by Fraunhofer, 49 by
AstraZeneca, and 198 by GVK BIO. A total of 47 patents were
annotated by at least three of the groups (three patents were
annotated by all four groups).
Initial harmonized set
The initial harmonized set, prior to disambiguation, was
generated over the 47 common patents, yielding a total of
35,337 annotations (Table 2). The results show that IUPAC
names and generic names have been annotated significantly more
than any other chemical type, as has also been shown previously
[13]. On the other hand, InChIs, CAS registry numbers and
SMILES are rarely seen in these chemical patents. Also, a
considerable number of diseases, targets, and MOAs have been
annotated.
Inter-annotator agreement prior to disambiguation
Table 3 shows the inter-annotator agreement between the
groups and the harmonized set prior to disambiguation. There is
generally a higher inter-annotator agreement between individual
annotator groups and the harmonized set than between pairs of
groups. The best agreement was 0.78. The agreement between
groups ranged between 0.39 and 0.69. Investigation of the reasons
for some low agreements suggested that adding a disambiguation
step could resolve some of these disagreements.
Disambiguation
A set of 2,135 unique ambiguous terms, corresponding to
47,044 annotations, were provided to annotators for disambigu-
ation as described above. The annotators were able to make a
decision for 333 unique ambiguous terms, affecting 9,005
annotations. The results in Table 4 show that most difficulties
within the annotations were encountered between IUPAC names,
Table 7. Number of annotated terms and unique terms in the harmonized set and in the full patent set of the gold standard
corpus after disambiguation.
Harmonized set (47 Patents) Full set (198 Patents)
Unique terms Annotated terms Unique terms Annotated terms
IUPAC 5,325 14,377 50,893 135,603
Generic 881 8,384 14,305 169,133
Disease 1,256 3,776 4,503 20,229
Target 703 3,235 3,514 14,398
Trademark 994 2,366 3,365 9,574
Abbreviation 153 2,088 778 21,087
Formula 169 1,127 3,108 25,716
MOA 210 1,017 110 3,837
Registry Number 96 140 188 329
SMILES 21 21 166 166
CAS 5 6 47 53
InChI 0 0 0 0
Total 9,813 36,537 80,977 400,125
doi:10.1371/journal.pone.0107477.t007
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Generic names and Trademarks. Also 23 elements were found
that had been annotated 2,499 times with different entity types
throughout the corpus. Since elements should not be annotated
according to the guidelines, these terms were removed from the
corpus.
Inter-annotator agreement after disambiguation
After resolving the ambiguous terms, the harmonized set was
recalculated. This resulted in an increase of inter-annotator
agreement scores by 0.01 to 0.09 points (Table 5).
Recalculating the inter-annotator agreement by only consider-
ing text boundaries and disregarding the entity types, further
increases the agreement with up to 0.04 points. To analyze the
reasons behind some of the low agreements, inter-annotator
agreement scores were calculated for the main entity types
(Table 6). The major difficulty in the annotation was encountered
for non-systematic identifiers and MOAs, while identification of
targets, diseases, and systematic identifiers were made with higher
agreements.
The inter-annotator agreement between the groups and overall,
chemicals and systematic names were between 0.65 and 0.94. The
inter-annotator agreement for non-systematic terms between
Fraunhofer and the harmonized set was only 0.38. To investigate
the reasons behind this low agreement, we recalculated the inter-
annotator agreement between Fraunhofer and the harmonized set
by considering cases where one annotation was embedded within
the other annotation as an agreement. This only increased the
inter-annotator score to 0.46. Further analysis showed that
counting annotations that overlap as an agreement increased the
score to 0.62. The main reason for the remaining differences was
that annotators at Fraunhofer did not annotate formulas and had
low agreements with others within the generic terms.
Table 6 shows that apart from AstraZeneca, all groups
managed to gain a high inter-annotator agreement (0.82 to 0.86)
between diseases and the harmonized set. Further analysis showed
that the low inter-annotator agreement between AstraZeneca and
the harmonized set on diseases is due to annotation differences in
the boundaries. Calculating inter-annotator agreement on diseases
by also accepting embedded terms increased the agreement to
0.70.
The inter-annotator agreement between Fraunhofer and the
harmonized set for targets was only 0.57. Additional investigation
showed that accepting embedded terms increased the agreement
to 0.64.
The annotations of MOA for Fraunhofer and NextMove were
also greatly affected by how the boundaries were chosen. An
example is the term ‘‘mixed agonist’’ for which one group
annotated the whole term as MOA and the other only annotated
‘‘agonist’’ as MOA. Accepting such cases as an agreement
increases the agreement between NextMove and the harmonized
set from 0.17 to 0.72, and between Fraunhofer and the
harmonized set from 0.29 to 0.62.
The gold standard patent corpus
The gold standard patent corpus consists of two sets: the
harmonized corpus and the full corpus. The harmonized corpus
consists of 47 patents with a total of 36,537 annotations for 9,813
unique terms (Table 7). In addition, 1,239 OCR errors have been
annotated, of which 1,189 are spelling mistakes. The full patent
corpus of 198 patents contains only the GVK BIO annotations
with 400,125 annotations for 80,977 unique terms. The set
includes 5,096 OCR error annotations, of which 4,403 are spelling
mistakes.
Discussion and Conclusions
We have produced a gold standard chemical patent corpus
consisting of 198 full patents of which 47 patents have been
annotated by at least three annotators. The patent corpus contains
a selection of patents from WIPO, USPTO and EPO with
annotation of compounds, diseases, targets, and MOAs. We have
also annotated spelling errors for the mentioned entity types.
We have released the inter-annotator agreements along with the
gold standard corpus. Making inter-annotator agreement scores
available will hopefully prove to be useful for performance
assessment of automatic annotations of the patent corpus.
To our knowledge this is the first patent gold standard corpus
containing full patents with different entity types (chemicals and
their sub entities, diseases, MOAs, and targets). Patents are one of
the richest knowledge sources with high information content and
detailed description of chemistry and technology. Our annotation
process showed the complexity of the annotation task. The OCR
process added a significant level of noise to the text. A high inter-
annotator agreement was seen on the annotation of entities such as
systematic names. In contrast, we observed lower inter-annotator
agreements for non-systematic names and MOAs. This empha-
sizes the challenges in identifying named entities from patent text.
Annotation of OCR errors may also be helpful to improve patent
informatics systems by facilitating the development of algorithms
to correct such errors.
The annotated gold standard corpus should prove a valuable
resource for developing and evaluating patent text analytics
approaches.
Availability
The gold standard corpus is available through www.
biosemantics.org.
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